Effectiveness and tolerability of rabeprazole 20mg as once-daily monotherapy in treatment of erosive or ulcerative gastro-oesophageal reflux disease

Clinical Drug Investigation

Volumn 22, Issue 5, 2002, Pages 279-289

  De Freitas, José Alves ^a  

^a FAMECA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIMETIDINE; CISAPRIDE; LANSOPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE;

ADULT; ANXIETY; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DYSPHAGIA; DYSURIA; ENDOSCOPY; EROSIVE GASTRITIS; ESOPHAGITIS; FEMALE; GASTROESOPHAGEAL REFLUX; HEADACHE; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; SOMNOLENCE; TREATMENT OUTCOME; ULCER HEALING; VERTIGO;

EID: 0036091007     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222050-00002     Document Type: Article

References (33)

1. Critical issues in the management of gastroesophageal reflux disease
2. Rabeprazole: Pharmacokinetics and safety in the elderly
3. Current management of gastroesophageal reflux disease
4. Current practice and future perspectives in the management of gastro-oesophageal reflux disease
5. Medical therapy of GERD: Current state of the art
6. Pharmacological management of gastro-oesophageal reflux disease
7. Pathogenesis and treatment of acid peptic disorders: Comparison of proton pump inhibitors with other antiulcer agents
8. Proton pump inhibitors: New drugs and indications
9. Omeprazole or ranitidine in the treatment of reflux esophagitis: Results of a double-blind, randomized, Scandinavian multicenter study
10. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis: A controlled double blind trial of their efficacy and safety
11. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: A systematic overview
12. Long-term treatment with omeprazole for refractory reflux esophagitis: Efficacy and safety
13. Rabeprazole
14. Rabeprazole. A review of its use in acid-related gastrointestinal disorders
15. Rabeprazole in treatment of acid peptic disease: Results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD)
16. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects
17. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro-oesophageal reflux disease
18. Review article: Drug interactions with agents used to treat acid-related disease
19. Rabeprazole: Pharmacokinetics in patients with stable, compensated cirrhosis
20. Efficacy of rabeprazole once daily for acid-related disorders
21. Double-blind, placebo-controlled comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease
22. Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once dally, in the healing of erosive gastroesophageal reflux disease
23. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease
24. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: A double-blind, multicenter, European trial
25. Healing and relapse rates in gastroesophageal reflux disease with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: Evidence from randomized clinical trials
26. Rabeprazole is comparable in efficacy to omeprazole in erosive GERD and provides more rapid heartburn relief
27. Rabeprazole provides better heartburn relief compared to omeprazole in the first 3 days and 7 days of treatment
28. Rabeprazole relieves symptom distress in patients with non-erosive gastro-oesophageal reflux disease
29. Rabeprazole prevents recurrence of pathology and symptoms in patients with healed erosive or ulcerative gastroesophageal reflux disease
30. New-generation proton pump inhibitors: Overcoming the limitations of early-generation agents
31. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole
32. Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis